Startup Profile
Deep LS

Introduce yourselves

Tell us in three sentences who you are

Deep LS supports pharmaceutical companies in improving their drug development. State-of-the-art AI methods are used to generate and optimize suggestions for new drug candidates.

What challenge does your startup address and how did the idea for it come about?

The two founders Daniel Soric and Felix Kamieth identified considerable potential for optimization in the drug discovery process due to a lack of digitalization. This process is currently very lengthy and costly, but can be significantly accelerated with the help of the AI-based solution from Deep LS. Initially, the founders had to build up a reputation and create acceptance.

Can you briefly explain how your solution operates and to what extent AI supports this solution?

AI is the core of Deep LS. Using the latest AI methods such as latent diffusion, Deep LS generates new active ingredient candidates and optimizes their properties according to the customer’s wishes.

To what extent are your solutions adaptable or customizable to meet the specific requirements and objectives of different pharma and biopharma projects?

The issue of designing active substances with specific properties is not limited to the pharmaceutical industry, but also occurs in other sectors, e.g. crop protection, chemicals, cosmetics or the food industry.
Our software solution is a platform that can be easily individualized to meet customer requirements. We are constantly expanding it.

What successful approaches from other industries have been transferred to pharmaceutical research and how do these contribute to the efficiency of your services?

The generative AI approach is a technology of the future. Initial successes have been demonstrated by ChatGPT. The innovative approach of generative AI can also be used for process optimization in pharmaceutical research. Generative AI reduces computing power and generates new molecules without the need for prior comparison with large databases.

How do you plan to grow your startup in the next 1-2 years?

The first growth driver is the switch from the current project-based business model to a platform model with recurring revenues. License income from molecules developed jointly with partners will boost growth.

AI Startup RISING gives us access to a large network of experts and coaches. The workshops help us as a young company to constantly adopt new perspectives and work on ourselves.

Deep LS